M&A Deal Summary

ATAI Life Sciences AG Acquires Psyber

On April 7, 2021, ATAI Life Sciences AG acquired life science company Psyber

Acquisition Highlights
  • This is ATAI Life Sciences AG’s 3rd transaction in the Life Science sector.
  • This is ATAI Life Sciences AG’s 2nd transaction in the United States.
  • This is ATAI Life Sciences AG’s 1st transaction in Delaware.

M&A Deal Summary
Date 2021-04-07
Target Psyber
Sector Life Science
Buyer(s) ATAI Life Sciences AG
Deal Type Add-on Acquisition

Target

Psyber

Delaware, United States
Psyber is a developer of an interventions to improve various mental health disorders and induce behavioural changes through brain computer interface (BCI)-enabled digital therapeutics (DTx). Psyber is based in Delaware.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ATAI Life Sciences AG

Munchen, Germany
Category Company
Sector Life Science
DESCRIPTION

ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. ATAI Life Sciences is based in München, Germany.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 3 of 3
State (Delaware) 1 of 1
Country (United States) 2 of 2
Year (2021) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-12 Recognify

Berlin, Germany

Recognify is an entity developing a treatment for Cognitive Impairment Associated with Schizophrenia ("CIAS"). Recognify's lead compound, "RL-007", previously called FSV7-007, has exhibited a modulating effect on three mechanisms that are central to learning and memory: the cholinergic, NMDA, and GABA type B receptor systems.

Buy -
Mergr

Product

Company

Legal